Julie Sheldon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6338574/publications.pdf

Version: 2024-02-01

147566 143772 3,791 60 31 57 h-index citations g-index papers 61 61 61 4204 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Viral Quasispecies Evolution. Microbiology and Molecular Biology Reviews, 2012, 76, 159-216.	2.9	811
2	Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents., 1998, 77, 817-820.		251
3	Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir. Antiviral Therapy, 2005, 10, 727-734.	0.6	249
4	Bone Marrow Failure Associated with Human Herpesvirus 8 Infection after Transplantation. New England Journal of Medicine, 2000, 343, 1378-1385.	13.9	224
5	Motherâ€toâ€Child Transmission of Human Herpesvirus–8 in South Africa. Journal of Infectious Diseases, 2004, 190, 1068-1075.	1.9	125
6	The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-negative hepatitis B virus strains. Hepatology, 2009, 49, 1158-1165.	3.6	118
7	Hepatitis B virus escape mutants induced by antiviral therapy. Journal of Antimicrobial Chemotherapy, 2008, 61, 766-768.	1.3	115
8	Transient Angiolymphoid Hyperplasia and Kaposi's Sarcoma after Primary Infection with Human Herpesvirus 8 in a Patient with Human Immunodeficiency Virus Infection. New England Journal of Medicine, 1998, 338, 1585-1590.	13.9	110
9	HUMAN HERPES VIRUS-8 AND OTHER RISK FACTORS FOR KAPOSI'S SARCOMA IN KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1999, 67, 1236-1242.	0.5	107
10	Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype. Journal of Virology, 2013, 87, 7593-7607.	1.5	88
11	Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antiviral Therapy, 2005, 10, 727-34.	0.6	88
12	Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2006, 57, 709-713.	1.3	79
13	Does Treatment of Hepatitis B virus (HBV) Infection Reduce Hepatitis Delta virus (HDV) Replication in HIV-HBV-HDV-Coinfected Patients?. Antiviral Therapy, 2008, 13, 97-102.	0.6	76
14	Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus. Journal of Virology, 2014, 88, 12098-12111.	1.5	74
15	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. Journal of Clinical Microbiology, 2015, 53, 219-226.	1.8	74
16	Risk factors for human Herpesvirus 8 infection and AIDS-associated Kaposi's sarcoma among men who have sex with men in a European multicentre study. International Journal of Cancer, 2006, 120, 1129-1135.	2.3	67
17	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. Aids, 2006, 20, 1951-1954.	1.0	64
18	Extinction of Hepatitis C Virus by Ribavirin in Hepatoma Cells Involves Lethal Mutagenesis. PLoS ONE, 2013, 8, e71039.	1.1	60

#	Article	IF	Citations
19	Recombination in human herpesvirus-8 strains from Uganda and evolution of the K15 gene. Journal of General Virology, 2001, 82, 2393-2404.	1.3	58
20	Kaposi's sarcoma-associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	2.5	56
21	Selection of Hepatitis B Virus (HBV) Vaccine Escape Mutants in HBV-Infected and HBV/HIV-Coinfected Patients Failing Antiretroviral Drugs With Anti-HBV Activity. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 279-282.	0.9	54
22	Hepatitis B Virus Genotypes and Lamivudine Resistance Mutations in HIV/Hepatitis B Virus-Coinfected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 557-561.	0.9	53
23	Evidence for horizontal and not vertical transmission of human herpesvirus 8 in children born to human immunodeficiency virus-infected mothers. Pediatric Infectious Disease Journal, 1999, 18, 795-799.	1.1	50
24	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 2000, 96, 2355-2357.	0.6	46
25	Kaposi's sarcoma associated herpesvirus (KSHV) or human herpesvirus 8 (HHV8). Virus Research, 2001, 82, 115-126.	1.1	46
26	Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses, 2015, 7, 3995-4046.	1.5	42
27	Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus. Antimicrobial Agents and Chemotherapy, 2016, 60, 3786-3793.	1.4	42
28	Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs, 2008, 13, 1-19.	1.0	41
29	Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: Variable frequencies found in a multicenter serological study. Journal of Medical Virology, 2000, 62, 498-504.	2.5	36
30	Viral fitness: history and relevance for viral pathogenesis and antiviral interventions. Pathogens and Disease, 2019, 77, .	0.8	36
31	Telbivudine: a new option for the treatment of chronic hepatitis B. Expert Opinion on Biological Therapy, 2007, 7, 751-761.	1.4	35
32	Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. Journal of Medical Virology, 2006, 78, 1599-1608.	2.5	33
33	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. Journal of Infection, 2007, 54, 173-179.	1.7	32
34	Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2007, 16, 1171-1181.	1.9	25
35	Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1). Journal of Clinical Microbiology, 2007, 45, 88-92.	1.8	24
36	Liver-expressed $\langle i \rangle$ Cd302 $\langle i \rangle$ and $\langle i \rangle$ Cr11 $\langle i \rangle$ limit hepatitis C virus cross-species transmission to mice. Science Advances, 2020, 6, .	4.7	23

#	Article	IF	CITATIONS
37	Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. Antiviral Therapy, 2008, 13, 97-102.	0.6	23
38	Human herpes virus 8 infection in kidney transplant patients in Belgium. Nephrology Dialysis Transplantation, 2000, 15, 1443-1445.	0.4	22
39	Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient. Aids, 2009, 23, 268-272.	1.0	22
40	Molecular basis of interferon resistance in hepatitis C virus. Current Opinion in Virology, 2014, 8, 38-44.	2.6	22
41	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. Journal of Antimicrobial Chemotherapy, 2008, 62, 626-627.	1.3	18
42	Supercritical fluid extraction of heather (Calluna vulgaris) and evaluation of anti-hepatitis C virus activity of the extracts. Virus Research, 2015, 198, 9-14.	1.1	18
43	Efficient acute and chronic infection of stem cell-derived hepatocytes by hepatitis C virus. Gut, 2020, 69, 1659-1666.	6.1	18
44	Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2007, 45, e118-e120.	2.9	17
45	Hepatitis C virus-mediated Aurora B kinase inhibition modulates inflammatory pathway and viral infectivity. Journal of Hepatology, 2015, 63, 312-319.	1.8	17
46	No Increased Human Herpesvirus 8 Seroprevalence in Patients With HIV-Associated Non-Hodgkin's Lymphoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 182-184.	0.9	15
47	B-lymphotropic viruses in a novel tropical splenic lymphoma. British Journal of Haematology, 2001, 112, 161-166.	1.2	14
48	Nonmalignant disease associated with human herpesvirus 8 reactivation in patients who have undergone autologous peripheral blood stem cell transplantation. Blood, 2000, 96, 2355-2357.	0.6	14
49	Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. Aids, 2006, 20, 451-453.	1.0	10
50	Management of hepatitis B virus co-infection on and off antiretroviral therapy. Current HIV/AIDS Reports, 2008, 5, 86-93.	1.1	9
51	No Increased Human Herpesvirus 8 Seroprevalence in Patients With HIV-Associated Non-Hodgkin's Lymphoma. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 26, 182-184.	0.9	8
52	Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIVâ€Infected Patient despite Continuous HCV Replication. Clinical Infectious Diseases, 2009, 48, 1634-1635.	2.9	8
53	Lack of anti-HIV activity of entecavir in an HIV patient coinfected with hepatitis B and delta viruses. Aids, 2007, 21, 2253-2254.	1.0	6
54	Interdependent Impact of Lipoprotein Receptors and Lipid-Lowering Drugs on HCV Infectivity. Cells, 2021, 10, 1626.	1.8	5

#	Article	IF	CITATIONS
55	Kaposi's sarcomaâ€associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays. Journal of Medical Virology, 2001, 65, 123-132.	2.5	3
56	Complications in treating chronic hepatitis B in patients with HIV. Expert Opinion on Pharmacotherapy, 2005, 6, 2831-2842.	0.9	2
57	Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. Aids, 2007, 21, 652-653.	1.0	2
58	Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents., 1998, 77, 817.		2
59	Quasispecies and Drug Resistance. , 2017, , 123-147.		2
60	Quasispecies and Drug Resistance. , 2014, , 1-22.		0